NCT03665597 2025-02-10KEYNOTE-555Merck Sharp & Dohme LLCPhase 1 Completed138 enrolled 34 charts 2 FDA
NCT01121588 2025-01-23Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)PfizerPhase 1 Terminated44 enrolled 22 charts 1 FDA
NCT02564900 2024-01-22Study of DS-8201a in Subjects With Advanced Solid Malignant TumorsDaiichi SankyoPhase 1 Completed292 enrolled 35 charts 1 FDA
NCT02054806 2023-10-30MK-3475-028Merck Sharp & Dohme LLCPhase 1 Completed477 enrolled 14 charts 1 FDA
NCT02508532 2022-06-21(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid TumorsBlueprint Medicines CorporationPhase 1 Completed250 enrolled 36 charts 2 FDA
NCT01077544 2020-12-29A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)NovartisPhase 1 Completed15 enrolled 20 charts 1 FDA